@article{fdi:010078091,
  title = {{M}ass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate {P}lasmodium falciparum have only a transient impact on {P}lasmodium vivax : findings from randomised controlled trials},
  author = {{P}hommasone, {K}. and van {L}eth, {F}. and {P}eto, {T}. {J}. and {L}andier, {J}ordi and {N}guyen, {T}. {N}. and {T}ripura, {R}. and {P}ongvongsa, {T}. and {L}win, {K}. {M}. and {K}ajeechiwa, {L}. and {T}hwin, {M}. {M}. and {P}arker, {D}. {M}. and {W}iladphaingern, {J}. and {N}osten, {S}. and {P}roux, {S}. and {N}guon, {C}. and {D}avoeung, {C}. and {R}ekol, {H}. and {A}dhikari, {B}. and {P}romnarate, {C}. and {C}hotivanich, {K}. and {H}anboonkunupakarn, {B}. and {J}ittmala, {P}. and {C}heah, {P}. {Y}. and {D}horda, {M}. and {I}mwong, {M}. and {M}ukaka, {M}. and {P}eerawaranun, {P}. and {P}ukrittayakamee, {S}. and {N}ewton, {P}. {N}. and {T}hwaites, {G}. {E}. and {D}ay, {N}. {P}. {J}. and {M}ayxay, {M}. and {H}ien, {T}. {T}. and {N}osten, {F}. {H}. and {C}obelens, {F}. and {D}ondorp, {A}. {M}. and {W}hite, {N}. {J}. and von {S}eidlein, {L}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground {M}ass administrations of antimalarial drugs ({MDA}) have reduced the incidence and prevalence of {P}. falciparum infections in a trial in the {G}reater {M}ekong {S}ubregion. {H}ere we assess the impact of the {MDA} on {P}. vivax infections. {M}ethods {B}etween {M}ay 2013 and {J}uly 2017, four villages in each {M}yanmar, {V}ietnam, {C}ambodia and {L}ao {PDR} were selected based on high prevalence of {P}. falciparum infections. {E}ight of the 16 villages were randomly assigned to receive {MDA} consisting of three-monthly rounds of three-day courses of dihydroartemisinin-piperaquine and, except in {C}ambodia, a single low-dose of primaquine. {C}ross-sectional surveys were conducted at quarterly intervals to detect {P}lasmodium infections using ultrasensitive q{PCR}. {T}he difference in the cumulative incidence between the groups was assessed through a discrete time survival approach, the difference in prevalence through a difference-in-difference analysis, and the difference in the number of participants with a recurrence of {P}. vivax infection through a mixed-effect logistic regression. {R}esults 3,790 (86%) residents in the intervention villages participated in at least one {MDA} round, of whom 2,520 (57%) participated in three rounds. {T}he prevalence of {P}. vivax infections fell from 9.31% to 0.89% at month 3 but rebounded by six months to 5.81%. {T}here was no evidence that the intervention reduced the cumulative incidence of {P}.vivax infections (95% confidence interval [{CI}] {O}dds ratio ({OR}): 0.29 to 1.36). {S}imilarly, there was no evidence of {MDA} related reduction in the number of participants with at least one recurrent infection ({OR}: 0.34; 95% {CI}: 0.08 to 1.42). {C}onclusion {MDA} with schizontocidal drugs had a lasting effect on {P}. falciparum infections but only a transient effect on the prevalence of {P}. vivax infections. {R}adical cure with an 8-aminoquinoline will be needed for the rapid elimination of vivax malaria.},
  keywords = {{VIET} {NAM} ; {CAMBODGE} ; {LAOS} ; {MYANMAR}},
  booktitle = {},
  journal = {{PL}o{S} {O}ne},
  volume = {15},
  numero = {2},
  pages = {e0228190 [16 ]},
  ISSN = {1932-6203},
  year = {2020},
  DOI = {10.1371/journal.pone.0228190},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078091},
}